Boston Scientific beats Q3 expectations, raises 2025 guidance amid strong performance in key franchises like WATCHMAN and FARAPULSE/pulsed-field ablation.
Struggling Saints face tough test against surging Rams in key NFC matchup
Boston Scientific beats Q3 expectations, raises 2025 guidance amid strong performance in key franchises like WATCHMAN and FARAPULSE/pulsed-field ablation.
Struggling Saints face tough test against surging Rams in key NFC matchup